公开(公告)号：US20230167409A1

公开(公告)日：2023-06-01

申请号：US17921180

申请日：2021-04-26

Applicant: TOKAI UNIVERSITY EDUCATIONAL SYSTEM ,  NIPPON ZOKI PHARMACEUTICAL CO., LTD.

Inventor： Daisuke SAKAI ,  Yoshihiko NAKAMURA ,  Erika MATSUSHITA

IPC: C12N5/077 ,  A61K35/32 ,  C07K14/71

CPC classification number: C12N5/0655 ,  A61K35/32 ,  C07K14/71 ,  C12N2506/13 ,  C12N2500/76 ,  C12N2501/115 ,  C12N2533/32

Abstract: A method of culturing a cell population containing cartilage-derived cells positive for expression of Tie2 (cartilage-derived Tie2-positive cells), the method including culturing a cell population containing cartilage-derived Tie2-positive cells in a culture medium containing at least one kind of Tie2 expression enhancer other than growth factors (e.g., an extract derived from a plant of the genus Cinnamomum). This culturing method is preferably performed in cultureware having a culture surface coated with a coating agent (e.g., a polylysine-containing agent).

公开(公告)号：US11433031B2

公开(公告)日：2022-09-06

申请号：US17222237

申请日：2021-04-05

Applicant: NIPPON ZOKI PHARMACEUTICAL CO., LTD.

Inventor： Hiroshi Sakamoto ,  Kunio Komai ,  Kenji Sakakibara ,  Hirokazu Banba ,  Kiyoshi Fukuda

IPC: A61K9/20 ,  A61K47/02 ,  A61K47/10 ,  A61K31/167 ,  A61K47/30 ,  A61K47/38 ,  A61K47/32 ,  A61K47/26 ,  A61K47/20

Abstract: A method for manufacturing a preparation which contains acetaminophen at a high content, in particular, a miniaturized tablet (conventional tablets, sustained-release tablets, etc.) which have excellent elution properties, preferable hardness and high drug content uniformity, and a premix drug substance of acetaminophen which has improved manufacturability. According to the method in which acetaminophen having a preset particle size is used for manufacturing a preparation, the flowability of acetaminophen can be improved so that secondary agglomeration can be suppressed and manufacturing efficiency can be elevated. Thus, this method is highly useful for manufacturing an acetaminophen preparation having improved administrability, for example, a reduced size.

公开(公告)号：US20220096561A1

公开(公告)日：2022-03-31

申请号：US17426349

申请日：2019-01-30

Applicant: Jun LIU ,  NIPPON ZOKI PHARMACEUTICAL CO., LTD.

Inventor： Jun LIU ,  Wang LIAO ,  Wenli FANG ,  Shengnuo FAN ,  Yuqiu ZHENG

IPC: A61K35/30 ,  C12N5/079

Abstract: An inhibiting or alleviating agent for inflammation in the brain comprising an extract from inflamed tissue inoculated with vaccinia virus as the active ingredient. In another aspect, the invention relates to a determination or evaluation method of an extract from inflamed tissue inoculated with vaccinia virus or an agent comprising the extract, characterized in that the inhibition of the expression of pro-inflammatory cytokines and/or NF-κB pathway related proteins induced by the promotion of expression of BDNF in cultivated glial cells is used as an indicator. In still another aspect, the invention also relates to a use of an extract from inflamed tissue inoculated with vaccinia virus in the production of the inhibiting or alleviating agent for inflammation in the brain.

公开(公告)号：US10711292B2

公开(公告)日：2020-07-14

申请号：US14858396

申请日：2015-09-18

Applicant: NIPPON ZOKI PHARMACEUTICAL CO., LTD. ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Koichi Masuda ,  Mitsuru Naiki

IPC: A61K35/36 ,  C12Q1/02 ,  A61K35/32 ,  A61K35/76 ,  G01N33/50

Abstract: The synthesis of collagen and proteoglycan in chondrocytes, such as intervertebral disc cells, articular chondrocytes and meniscal cells is promoted by administration of an extract from inflamed tissue inoculated with vaccinia virus.

公开(公告)号：US20190209622A1

公开(公告)日：2019-07-11

申请号：US16336236

申请日：2017-09-22

Applicant: OSAKA UNIVERSITY ,  NIPPON ZOKI PHARMACEUTICAL CO., LTD.

Inventor： Hiroyuki TANAKA ,  Tsuyoshi MURASE ,  Hideki YOSHIKAWA ,  Hiroki FUJISAWA

IPC: A61K35/36 ,  G01N33/50 ,  C12Q1/6876 ,  A61P25/02

CPC classification number: A61K35/36 ,  A61P25/02 ,  C12N7/00 ,  C12N2710/24132 ,  C12Q1/6876 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/5023 ,  G01N33/5058 ,  G01N2333/07 ,  G01N2800/7095

Abstract: A Schwann cell differentiation promoting agent, a peripheral nerve regeneration promoting agent, or the like contain an extract from inflamed tissues inoculated with vaccinia virus. The extract from inflamed tissues inoculated with vaccinia virus promotes differentiation of Schwann cells and regeneration of a peripheral nerve. Therefore, a preparation containing the extract from inflamed tissues inoculated with vaccinia virus is useful as a Schwann cell differentiation promoting agent, a peripheral nerve regeneration promoting agent, or the like.

公开(公告)号：US20190038677A1

公开(公告)日：2019-02-07

申请号：US16073986

申请日：2017-01-27

Applicant: NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY ,  NIPPON ZOKI PHARMACEUTICAL CO., LTD.

Inventor： Kazuhide INAGE ,  Kazuhisa TAKAHASHI ,  Seiji OHTORI ,  Sumihisa ORITA

IPC: A61K35/36 ,  A61P21/00 ,  A61K9/00 ,  A61K35/76

Abstract: A medicament is useful for prevention or treatment of muscle injury. A novel medical use of an extract from inflamed tissues inoculated with vaccinia virus, and more particularly, a preventing or therapeutic agent for muscle injury containing the extract as an active ingredient. The preventing or therapeutic agent for muscle injury contains the extract as an active ingredient is extremely useful as a highly effective and highly safe medicament.

公开(公告)号：US20180258047A1

公开(公告)日：2018-09-13

申请号：US15755275

申请日：2016-08-26

Applicant: NIPPON ZOKI PHARMACEUTICAL CO., LTD.

Inventor： Taizo ITO ,  Xiaoming LIAO ,  Zihua LI

IPC: C07D223/04 ,  C07D223/14

Abstract: An object of the present invention is to provide a novel tetrahydroazepine compound and a process for producing the same.The present invention relates to a tetrahydroazepine compound represented by the formula (10) or a salt thereof, anda process for producing the said compound or a salt thereof. (In the formula, R1 is an optionally substituted alkyl group, R2 is an optionally substituted alkyl group and one of the X—Y bond and the Y—Z bond is a carbon-carbon double bond and the other is a carbon-carbon single bond.)

公开(公告)号：US10004716B2

公开(公告)日：2018-06-26

申请号：US15127618

申请日：2015-03-19

Applicant: NIPPON ZOKI PHARMACEUTICAL CO., LTD.

Inventor： Mitsuru Naiki ,  Takumi Numazawa ,  Hiroki Fujisawa

IPC: A61K31/37 ,  A61K9/00 ,  A61K31/635 ,  A61K31/4433 ,  A61K31/381

CPC classification number: A61K31/37 ,  A61K9/007 ,  A61K31/381 ,  A61K31/4433 ,  A61K31/635 ,  C07D311/12 ,  C07D311/18 ,  C07D405/12 ,  C07D409/12

Abstract: A method for prophylactically or therapeutically treating an inflammatory disease and/or degenerative intervertebral disk disease in a subject is disclosed. The method includes administering to the subject an effective amount of a coumarin derivative represented by formula (I), or a pharmaceutically acceptable salt or hydrate thereof: Each of R1 and R2 is independently (a) phenyl optionally substituted with alkoxy, alkyl, cyano, nitro, hydroxy, trifluoromethyl, amino, carboxy, alkoxycarbonyl, phenyl, or one or two halogen(s), (b) pyridyl, (c) alkyl, or (d) thienyl.

公开(公告)号：US20170065563A1

公开(公告)日：2017-03-09

申请号：US15122082

申请日：2015-02-25

Applicant: NIPPON ZOKI PHARMACEUTICAL CO., LTD.

Inventor： Kazuharu IENAGA

IPC: A61K31/4166 ,  A61K9/20 ,  A61K9/28 ,  A61K9/00

CPC classification number: A61K31/4166 ,  A61K9/0053 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2813 ,  A61K9/2853 ,  A61K9/2866

Abstract: An object of the present invention is to provide a pharmaceutical agent which is administered to a patient with chronic kidney disease in which the progress of worsening of renal function is rapid whereby the progress of the symptom is suppressed or improved.The present invention relates to a progress-suppressing or improving agent for chronic kidney disease containing 5-hydroxy-1-methylhydantoin as an active ingredient. The pharmaceutical agent of the present invention showed a significant effect in a patient with chronic kidney disease where progress of the renal function decrease is rapid. The present pharmaceutical agent is very useful as a highly safe pharmaceutical agent which suppresses or improves the progress of worsening of the renal function of a patient with rapidly progressive chronic kidney disease for which there has been no effective therapeutic agent being simply and easily ingestible.

Abstract translation: 本发明涉及含有5-羟基-1-甲基乙内酰脲作为活性成分的慢性肾脏疾病进展抑制或改善剂。 本发明的药剂在慢性肾脏疾病患者中显示出显着的效果，其中肾功能的进展快速降低。 本发明的药剂作为高度安全的药剂是非常有用的，其抑制或改善快速进行性慢性肾脏疾病的患者的肾功能恶化的进展，其中没有有效的治疗剂简单且容易地摄入。

公开(公告)号：US09365533B2

公开(公告)日：2016-06-14

申请号：US14429300

申请日：2013-09-20

Applicant: NIPPON ZOKI PHARMACEUTICAL CO., LTD.

Inventor： Mitsuru Naiki ,  Tomoyuki Okada ,  Kazuyoshi Sawada ,  Takashi Ogino

IPC: C07D311/02 ,  C07D311/12

CPC classification number: C07D311/12 ,  A61K31/352 ,  C07D311/18 ,  C07D405/12 ,  C07D409/12

Abstract: A novel coumarin derivative or a pharmaceutically acceptable salt thereof and also to provide a pharmaceutical agent containing such a compound as an active ingredient is provided. The coumarin derivative or a pharmaceutically acceptable salt thereof exhibits an excellent suppressive action to the destruction of cartilage and suppressive action to the proliferation of synovial cells in a pharmacological test where the release of sulfated glycosaminoglycans (sGAG) and the proliferation of synovial cells are used as indicators whereby it is very useful as an active ingredient of a pharmaceutical composition such as a preventive or therapeutic agent for arthropathy such as osteoarthritis or chronic rheumatoid arthritis.

Abstract translation: 提供了一种新型香豆素衍生物或其药学上可接受的盐，并且还提供含有这种化合物作为活性成分的药剂。 香豆素衍生物或其药学上可接受的盐在药理学试验中对软骨破坏和对滑膜细胞增殖的抑制作用显示出优异的抑制作用，其中硫酸化糖胺聚糖（sGAG）的释放和滑膜细胞的增殖被用作 指标，其作为药物组合物的有效成分非常有用，例如关节病如骨关节炎或慢性类风湿性关节炎的预防或治疗剂。